scispace - formally typeset
C

Cinzia Lanzi

Researcher at University of Milan

Publications -  76
Citations -  7949

Cinzia Lanzi is an academic researcher from University of Milan. The author has contributed to research in topics: Receptor tyrosine kinase & Heparanase. The author has an hindex of 32, co-authored 73 publications receiving 7351 citations. Previous affiliations of Cinzia Lanzi include Sigma-Tau.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal Article

TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.

TL;DR: The isolation and characterization of one of the thyroid TRK oncogenes, designated TRK-T1 is described, which is created by an intrachromosomal rearrangement that juxtaposes the 5' end of the TPR gene to the TRK tyrosine kinase domain.
Journal ArticleDOI

Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.

TL;DR: Results indicate that MGR3 is directed against a determinant located in the p 185HER2 ligand binding site and may compete with the p185HER2ligand, but is incapable of inducing a complete mitotic signal.
Journal ArticleDOI

Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma

TL;DR: The antitumor efficacy and oral bioavailability of RPI-1 support its therapeutic potential and Ret oncoproteins represent exploitable targets for therapeutic intervention in MEN2A-associated medullary thyroid carcinoma.
Journal ArticleDOI

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

TL;DR: In this article, the authors explored the molecular mechanisms involved in primary resistance to PLX4032 and investigated its effects on cell proliferation and signaling in a panel of 27 genetically characterized patient-derived melanoma cell lines.